Prognostic Factors Including Proliferation Markers Ki-67, Bax, and Bcl-2 in Temporal Bone Paraganglioma

Overview

Journal Skull Base Surg

Publisher Thieme

Date 1997 Jan 1

PMID 17171028

Authors

M Gjuric

U Volker

A Katalinic

S R Wolf

Affiliations

Soon will be listed here.

Abstract

Valuable criteria with which to predict the clinical behavior of the temporal bone paraganglioma or the response to treatment are lacking. The analysis of markers of cell proliferation is a possibility to estimate the prognosis. Extensive patient data on 40 temporal bone paragangliomas were gathered over the years and correlated with the data obtained by staining histologic sections with bcl-2, bax, and MIB I markers of cellular proliferation. The immunohistochemistry was in all cases negative for bcl-2, positive for bax, and for Ki-67 positive in 20% of tumors. The scores for Ki-67 did not correlate with the majority of clinical parameters, except for treatment modality, preoperative hearing loss, and cranial nerve involvement. The tendency toward poorer hearing and a higher incidence of preoperative lower cranial nerve palsies was demonstrated in patients with higher Ki-67 scores. Furthermore, the higher rate of subtotal tumor removals in these patients reveals technical difficulties in accomplishing a radical removal, although the incidence of residual tumors was thus not affected. In view of the present information obtained with proliferation markers, the site of tumor origin still remains the most predictive variable for the course of the disease.

References

Ueda T, Aozasa K, Tsujimoto M, Ohsawa M, Uchida A, Aoki Y . Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer. 1989; 63(8):1607-11. DOI: 10.1002/1097-0142(19890415)63:8<1607::aid-cncr2820630827>3.0.co;2-1. View

Capella C, Riva C, Cornaggia M, Chiaravalli A, Frigerio B, Solcia E . Histopathology, cytology and cytochemistry of pheochromocytomas and paragangliomas including chemodectomas. Pathol Res Pract. 1988; 183(2):176-87. DOI: 10.1016/S0344-0338(88)80045-1. View

Brown J . Glomus jugulare tumors. Methods and difficulties of diagnosis and surgical treatment. Laryngoscope. 1967; 77(1):26-67. DOI: 10.1288/00005537-196701000-00004. View

Gerdes J, Lemke H, Baisch H, Wacker H, Schwab U, STEIN H . Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984; 133(4):1710-5. View

Gerdes J, Schwab U, Lemke H, STEIN H . Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983; 31(1):13-20. DOI: 10.1002/ijc.2910310104. View

Cattoretti G, Pileri S, Parravicini C, BECKER M, Poggi S, Bifulco C . Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol. 1993; 171(2):83-98. DOI: 10.1002/path.1711710205. View

Branica S, Sprem N, Danilovic Z, Seiwerth S . Immunohistochemistry of glomus jugulare and tympanicum tumors. Acta Med Croatica. 1993; 47(3):123-4. View

Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T . Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material. Acta Neuropathol. 1994; 87(1):47-54. DOI: 10.1007/BF00386253. View

Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius V, Niskanen E . Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 1995; 55(19):4471-8. View

10.

Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang H, Reed J . Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol. 1994; 145(6):1323-36. PMC: 1887502. View

11.

Green Jr J, Brackmann D, Nguyen C, Arriaga M, Telischi F, De La Cruz A . Surgical management of previously untreated glomus jugulare tumors. Laryngoscope. 1994; 104(8 Pt 1):917-21. DOI: 10.1288/00005537-199408000-00001. View

12.

Carrasco V, Rosenman J . Radiation therapy of glomus jugulare tumors. Laryngoscope. 1993; 103(11 Pt 2 Suppl 60):23-7. DOI: 10.1002/lary.1993.103.s60.23. View

13.

Gulya A . The glomus tumor and its biology. Laryngoscope. 1993; 103(11 Pt 2 Suppl 60):7-15. DOI: 10.1002/lary.1993.103.s60.7. View

14.

Milewski C . [Morphology and clinical aspects of paragangliomas in the area of the head-neck]. HNO. 1993; 41(11):526-31. View

15.

Oltvai Z, Milliman C, Korsmeyer S . Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993; 74(4):609-19. DOI: 10.1016/0092-8674(93)90509-o. View

16.

Gazzaniga P, Gradilone A, Vercillo R, Gandini O, Silvestri I, Napolitano M . Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. Int J Cancer. 1996; 69(2):100-4. DOI: 10.1002/(SICI)1097-0215(19960422)69:2<100::AID-IJC5>3.0.CO;2-4. View

17.

Lu Q, Abel P, Foster C, Lalani E . bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol. 1996; 27(2):102-10. DOI: 10.1016/s0046-8177(96)90362-7. View

18.

Thomas A, El Rouby S, Reed J, Krajewski S, Silber R, POTMESIL M . Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene. 1996; 12(5):1055-62. View

19.

McDonnell T, Troncoso P, Brisbay S, Logothetis C, Chung L, Hsieh J . Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992; 52(24):6940-4. View

20.

Gee M, Kliewer K, Hinton D . Nucleolar organizer regions in paragangliomas of the head and neck. Arch Otolaryngol Head Neck Surg. 1992; 118(4):380-3. DOI: 10.1001/archotol.1992.01880040038007. View